L&H replaces CEO amid lawsuits and shareholder concernsHead of Healthcare Solutions named chief execFacing several class action lawsuits and questions concerning revenue from its Korean business, Belgian firm Lernout & Hauspie
Head of Healthcare Solutions named chief exec
Facing several class action lawsuits and questions concerning revenue from its Korean business, Belgian firm Lernout & Hauspie announced that long-time president and CEO Gaston Bastiaens has stepped down. John Duerden, formerly president and CEO of Dictaphone and L&Hs Healthcare Solutions Group (HSG), will take on leadership of the speech technologies firm. Robert Schwager, who served under Duerden as general manager of Dictaphones healthcare business and L&H HSG, now takes over as president of L&H HSG. Bastiaens remains as a board member.
Bastiaens had come under fire in recent months for focusing on growing L&Hs business through acquisitions rather than concentrating on its core speech recognition products. In fact, the company has been broadening its technology base in the face of stiff competition in the speech and voice technologies field, where the major players include IBM, Nuance Communications, SpeechWorks, and Philips Electronics.
Duerden plans to focus on better integrating Dictaphone and Dragon Systems into L&Hs operations (HNN 4/5/00). Dictaphone and Dragon Systems are among half a dozen companies acquired by L&H in the past year. Industry sources estimate that L&H achieved a 60% share of the $6 billion medical transcription market through the Dictaphone acquisition. Dictaphones healthcare division accounted for $11.2 million of the companys $155 million in revenue for second quarter 2000.
Overall, L&H sales have fallen off everywhere except Korea. U.S. revenue totaled $48.2 million for second quarter 2000, up from $18.7 million in second quarter 1999, but the increase was attributed to revenue from Dictaphone and Dragon Systems. In addition, L&H stock has lost more than half its value since reaching a 52-week high of 72.5 in early spring. The stock closed at $29.75 per share on Aug. 30. In addition, the firm filed a shelf registration statement with the Securities and Exchange Commission in early August to sell up to $250 million in stock to pay off bank debt and provide working capital.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
2 Commerce Drive
Cranbury, NJ 08512